Notably, these findings have been corroborated by pharmacological studies: treatment with belumosudil, a selective ROCK2 inhibitor recently approved for the treatment of graft-versus-host disease (GVHD), has led to significant improvements in kidney histology and function in db/db mice, further supporting its therapeutic potential. The gene discussed is ROCK2; the disease is graft versus host disease.